Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C31H30FN5O4 |
| Molecular Weight | 555.5994 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC2=C(C=C1)N=C(CN3CCC(CC3)C4=NC(OCC5=CC=C(C=C5F)C#N)=CC=C4)N2C[C@@H]6CCO6
InChI
InChIKey=HYBAKUMPISVZQP-DEOSSOPVSA-N
InChI=1S/C31H30FN5O4/c32-25-14-20(16-33)4-5-23(25)19-41-30-3-1-2-26(35-30)21-8-11-36(12-9-21)18-29-34-27-7-6-22(31(38)39)15-28(27)37(29)17-24-10-13-40-24/h1-7,14-15,21,24H,8-13,17-19H2,(H,38,39)/t24-/m0/s1
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
136 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36433713/ |
40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DANUGLIPRON plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
245.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36433713/ |
80 mg 2 times / day steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DANUGLIPRON plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
415.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36433713/ |
120 mg 2 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DANUGLIPRON plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2424 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36433713/ |
40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DANUGLIPRON plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
4691 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36433713/ |
80 mg 2 times / day steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DANUGLIPRON plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
6953 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36433713/ |
120 mg 2 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DANUGLIPRON plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.373 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36433713/ |
40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DANUGLIPRON plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
5.543 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36433713/ |
80 mg 2 times / day steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DANUGLIPRON plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
5.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36433713/ |
120 mg 2 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DANUGLIPRON plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DN9IUI24GP
Created by
admin on Tue Apr 01 22:15:13 GMT 2025 , Edited by admin on Tue Apr 01 22:15:13 GMT 2025
|
PRIMARY | |||
|
300000028080
Created by
admin on Tue Apr 01 22:15:13 GMT 2025 , Edited by admin on Tue Apr 01 22:15:13 GMT 2025
|
PRIMARY | |||
|
11630
Created by
admin on Tue Apr 01 22:15:13 GMT 2025 , Edited by admin on Tue Apr 01 22:15:13 GMT 2025
|
PRIMARY | |||
|
HI-76
Created by
admin on Tue Apr 01 22:15:13 GMT 2025 , Edited by admin on Tue Apr 01 22:15:13 GMT 2025
|
PRIMARY | |||
|
2230198-02-2
Created by
admin on Tue Apr 01 22:15:13 GMT 2025 , Edited by admin on Tue Apr 01 22:15:13 GMT 2025
|
PRIMARY | |||
|
C177080
Created by
admin on Tue Apr 01 22:15:13 GMT 2025 , Edited by admin on Tue Apr 01 22:15:13 GMT 2025
|
PRIMARY | |||
|
134611040
Created by
admin on Tue Apr 01 22:15:13 GMT 2025 , Edited by admin on Tue Apr 01 22:15:13 GMT 2025
|
PRIMARY | |||
|
DTXSID601101457
Created by
admin on Tue Apr 01 22:15:13 GMT 2025 , Edited by admin on Tue Apr 01 22:15:13 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
